At the news
? BEARISHIMPACT 6/10 PRESS-RELEASE filed Jun 2, 2026 at 16:01 ET
NRx Pharmaceuticals announced an underwritten public offering of common stock, with an option for underwriters to purchase an additional 15%. The offering size is undisclosed, and proceeds will be used for working capital and general corporate purposes. This dilutive event comes as a clinical-stage biotech with no approved products, raising capital to fund operations.
- NRx Pharmaceuticals intends to offer shares of common stock in an underwritten public offering.
- Underwriter has a 30-day option to purchase up to an additional 15% of shares sold.
- BTIG, LLC is lead bookrunner; Lucid Capital Markets is joint bookrunning manager.
- Proceeds will be used for working capital and general corporate purposes.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access